Alfa Institute of Biomedical Sciences, Marousi, Athens, Greece.
Int J Infect Dis. 2012 Nov;16(11):e768-73. doi: 10.1016/j.ijid.2012.07.010. Epub 2012 Aug 22.
To identify risk factors for the development of Clostridium difficile infection (CDI) due to C. difficile BI/NAP1/027 strain.
PubMed and Scopus databases were searched for studies that sought to identify risk factors for CDI due to the BI/NAP1/027 strain. The technique of meta-analysis was applied.
Five studies compared CDI BI/NAP1/027 patients to CDI patients infected with non-BI/NAP1/027 strains, one compared CDI BI/NAP1/027 patients to non-CDI patients, and one provided data for both comparisons. The meta-analysis showed that fluoroquinolones were associated with a higher risk of CDI due to BI/NAP1/027 when compared to non-BI/NAP1/027 CDI (odds ratio (OR) 1.96, 95% confidence interval (95% CI) 1.37-2.80). A trend towards a lower risk for CDI due to BI/NAP1/027 was observed with cephalosporins when compared to non-BI/NAP1/027 CDI (OR 0.70, 95% CI 0.46-1.07). Prior macrolides were not associated with a higher risk for CDI BI/NAP1/027 when compared with non-BI/NAP1/027 CDI controls (OR 0.88, 95% CI 0.44-1.78). Clindamycin administration was associated with a lower risk for CDI due to BI/NAP1/027 when compared to non-BI/NAP1/027 CDI (OR 0.24, 95% CI 0.12-0.48). Age over 65 years was associated with an increased risk of CDI BI/NAP1/027 compared to non-BI/NAP1/027 CDI (OR 1.77, 95% CI 1.31-2.38).
Fluoroquinolones and age over 65 years were associated with a higher risk of CDI due to the BI/NAP1/027 strain. Clindamycin was associated with a lower risk of CDI due to BI/NAP1/027.
确定与 BI/NAP1/027 型艰难梭菌相关的艰难梭菌感染 (CDI) 发展的危险因素。
在 PubMed 和 Scopus 数据库中搜索旨在确定与 BI/NAP1/027 株相关的 CDI 危险因素的研究。应用荟萃分析技术。
五项研究将 BI/NAP1/027 型 CDI 患者与感染非 BI/NAP1/027 型菌株的 CDI 患者进行了比较,一项研究将 BI/NAP1/027 型 CDI 患者与非 CDI 患者进行了比较,一项研究提供了这两项比较的数据。荟萃分析表明,与非 BI/NAP1/027 CDI 相比,氟喹诺酮类药物与 BI/NAP1/027 相关的 CDI 风险更高(比值比 [OR] 1.96,95%置信区间 [95%CI] 1.37-2.80)。与非 BI/NAP1/027 CDI 相比,头孢菌素类药物与 BI/NAP1/027 相关的 CDI 风险呈降低趋势(OR 0.70,95%CI 0.46-1.07)。与非 BI/NAP1/027 CDI 对照组相比,先前使用大环内酯类药物与 BI/NAP1/027 CDI 的风险增加无关(OR 0.88,95%CI 0.44-1.78)。与非 BI/NAP1/027 CDI 相比,克林霉素的使用与 BI/NAP1/027 相关的 CDI 风险降低相关(OR 0.24,95%CI 0.12-0.48)。与非 BI/NAP1/027 CDI 相比,年龄大于 65 岁与 BI/NAP1/027 CDI 的风险增加相关(OR 1.77,95%CI 1.31-2.38)。
氟喹诺酮类药物和年龄大于 65 岁与 BI/NAP1/027 型艰难梭菌相关 CDI 的风险增加有关。克林霉素与 BI/NAP1/027 相关 CDI 的风险降低有关。